Divergence in the approach to tumor necrosis factor α-inhibitor recipients with coccidioidomycosis

Ashley L. Garrett; Stephen S. Cha; Elizabeth Wack; Janis E. Blair

doi:10.1007/s15010-017-1029-9

Divergence in the approach to tumor necrosis factor α-inhibitor recipients with coccidioidomycosis

Ashley L. Garrett, Stephen S. Cha, Elizabeth Wack, Janis E. Blair

Infectious Diseases

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Background: Tumor necrosis factor α-inhibitors (TNFIs) have been associated with increased risk of certain fungal infections, including coccidioidomycosis. The optimal treatment approach to coccidioidomycosis in TNFI recipients is unknown. Methods: We constructed an anonymous, voluntary survey for practicing pulmonary and infectious disease physicians in the state of Arizona regarding approach to TNFI patients with coccidioidomycosis. Results: There is no current consensus on managing these patients. Conclusions: Further research is necessary to determine the optimal approach to TNFI recipients with coccidioidomycosis.

Original language	English (US)
Pages (from-to)	1-5
Number of pages	5
Journal	Infection
DOIs	https://doi.org/10.1007/s15010-017-1029-9
State	Accepted/In press - Jun 2 2017

Keywords

Biologic response modifiers
Coccidioides
Coccidioidomycosis
Infliximab
Tumor necrosis factor α-inhibitors
Valley fever

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1007/s15010-017-1029-9

Cite this

@article{80a3ab1fd55c493a9b4f91e906da594f,

title = "Divergence in the approach to tumor necrosis factor α-inhibitor recipients with coccidioidomycosis",

abstract = "Background: Tumor necrosis factor α-inhibitors (TNFIs) have been associated with increased risk of certain fungal infections, including coccidioidomycosis. The optimal treatment approach to coccidioidomycosis in TNFI recipients is unknown. Methods: We constructed an anonymous, voluntary survey for practicing pulmonary and infectious disease physicians in the state of Arizona regarding approach to TNFI patients with coccidioidomycosis. Results: There is no current consensus on managing these patients. Conclusions: Further research is necessary to determine the optimal approach to TNFI recipients with coccidioidomycosis.",

keywords = "Biologic response modifiers, Coccidioides, Coccidioidomycosis, Infliximab, Tumor necrosis factor α-inhibitors, Valley fever",

author = "Garrett, {Ashley L.} and Cha, {Stephen S.} and Elizabeth Wack and Blair, {Janis E.}",

year = "2017",

month = jun,

day = "2",

doi = "10.1007/s15010-017-1029-9",

language = "English (US)",

pages = "1--5",

journal = "Infection",

issn = "0300-8126",

publisher = "Urban und Vogel",

}

TY - JOUR

T1 - Divergence in the approach to tumor necrosis factor α-inhibitor recipients with coccidioidomycosis

AU - Garrett, Ashley L.

AU - Cha, Stephen S.

AU - Wack, Elizabeth

AU - Blair, Janis E.

PY - 2017/6/2

Y1 - 2017/6/2

N2 - Background: Tumor necrosis factor α-inhibitors (TNFIs) have been associated with increased risk of certain fungal infections, including coccidioidomycosis. The optimal treatment approach to coccidioidomycosis in TNFI recipients is unknown. Methods: We constructed an anonymous, voluntary survey for practicing pulmonary and infectious disease physicians in the state of Arizona regarding approach to TNFI patients with coccidioidomycosis. Results: There is no current consensus on managing these patients. Conclusions: Further research is necessary to determine the optimal approach to TNFI recipients with coccidioidomycosis.

AB - Background: Tumor necrosis factor α-inhibitors (TNFIs) have been associated with increased risk of certain fungal infections, including coccidioidomycosis. The optimal treatment approach to coccidioidomycosis in TNFI recipients is unknown. Methods: We constructed an anonymous, voluntary survey for practicing pulmonary and infectious disease physicians in the state of Arizona regarding approach to TNFI patients with coccidioidomycosis. Results: There is no current consensus on managing these patients. Conclusions: Further research is necessary to determine the optimal approach to TNFI recipients with coccidioidomycosis.

KW - Biologic response modifiers

KW - Coccidioides

KW - Coccidioidomycosis

KW - Infliximab

KW - Tumor necrosis factor α-inhibitors

KW - Valley fever

UR - http://www.scopus.com/inward/record.url?scp=85020073895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020073895&partnerID=8YFLogxK

U2 - 10.1007/s15010-017-1029-9

DO - 10.1007/s15010-017-1029-9

M3 - Article

C2 - 28577242

AN - SCOPUS:85020073895

SN - 0300-8126

SP - 1

EP - 5

JO - Infection

JF - Infection

ER -

Divergence in the approach to tumor necrosis factor α-inhibitor recipients with coccidioidomycosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this